Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?

Lin Cao*; Sean D. Pokorney, MD, MBA*; Kathleen Hayden, PhD; Kathleen Welsh-Bohmer, PhD; L. Kristin Newby, MD, MHS

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and those afflicted have reduced quality of life, functional status, and cardiac performance.1 Patients with AF have a higher risk of stroke, heart failure, and premature death relative to patients without AF.2 It is estimated that 2.5% of the population worldwide has AF, and the prevalence of AF increases substantially with age, especially after 50 years of age.3 AF is more common among white persons than black persons, and men are at 1.5 times greater risk for developing AF than women.3,4 In the United States, about 2.3 million people currently have AF, and the numbers are increasing rapidly. It is predicted that by 2050, 5.6 million people in the United States will have AF, with more than half of those patients aged >80 years.3 This represents a 2.5-fold increase over 50 years, reflecting both the growing proportion of elderly persons in the population3 and the increasing rates of comorbidities associated with AF, including coronary artery disease, hypertension, and congestive heart failure.2

Although the prevalence of AF is increasing, cognitive disorders are also on the rise in tandem with the aging of the population. Patients with mild cognitive impairment have increased morbidity and lower quality of life relative to patients with normal cognitive function,5,6 and compared with those with normal cognition, patients with dementia have increased mortality.7 The diagnosis of mild cognitive impairment is made based on cognitive testing scores that are lower than expected for a patient’s age, typically due to memory, but these persons maintain independent functional status in terms of activities of daily living and instrumental activities of daily living.8 Patients are diagnosed with dementia when they have evidence of cognitive impairment on testing and this cognitive deficit affects their functional status.9

More than 20% of people aged >70 years have mild cognitive impairment.10 There are ≈800 000 cases of mild cognitive impairment and ≈560 000 cases of dementia annually in the United States, and patients who have progressed from mild cognitive impairment to dementia account for 75% of patients with dementia.11 The prevalence of dementia increases with age from about 5% of patients in their 70s to nearly 40% of patients in their 90s.12 The aging population is predicted to result in an increase in the prevalence of dementia such that >80 million people worldwide are expected to have dementia by 2040.13,14 Historically, patients were classified as having Alzheimer’s disease if they had neurodegenerative disease and vascular dementia or if they had cerebral vascular lesions. This was an oversimplification because most patients have a combination of neurodegenerative and vascular lesions contributing to the clinical phenotype of dementia.15

This review is intended to review the literature and present the current findings on the association between AF and cognitive decline. The focus is on whether evidence shows that AF is associated with cognitive impairment beyond the relationship with stroke.

**Literature Search Methods**

Series of PubMed literature searches were conducted. The searches were limited to articles written in English and were performed January 7, 2015. The search terms included atrial fibrillation and hypoperfusion, atrial fibrillation and cognitive function, atrial fibrillation and silent stroke, atrial fibrillation and covert stroke, atrial fibrillation and cognitive impairment, atrial fibrillation and dementia, cardiovascular and dementia, and cognitive decline. The search yielded 3279 unique articles, and the titles and abstracts were screened for relevance. The citations in all relevant articles were examined for additional...
Cognitive Function in Atrial Fibrillation  Cao et al

Cardiovascular Disease and Cognitive Impairment

The link between cardiovascular diseases and cognitive impairment has been well established. Coronary artery disease was associated with cognitive decline in a 6-year longitudinal study, and elevated risk scores for coronary heart disease, such as the Framingham Risk Score, were associated with cognitive decline in adults aged >50 years in both primarily white and primarily Hispanic populations. Blood pressure has been associated with cognitive decline, and this relationship includes hypertension, large variations in systolic blood pressure, and hypotension due to low cardiac output. A meta-analysis of 2937 heart failure patients and 14,848 control patients found that heart failure was associated with cognitive impairment (hazard ratio [HR] 1.62, 95% CI 1.48 to 1.79).

Cognitive Decline and Stroke

Stroke is a major cause of cognitive impairment, and even mild to moderate strokes cause long-term decline in cognitive function. A study by Tatemichi et al was designed to determine the association between stroke and cognitive domains (memory, orientation, verbal skills, visuospatial ability, abstract reasoning, and attention to detail) affected by stroke. The study evaluated 227 patients 3 months after stroke and 240 control patients with no history of stroke. Impairment of memory, orientation, language, and attention were associated with stroke. Among a group of patients with cerebral small vessel disease, the number of lacunar infarcts at baseline was associated with cognitive impairment 3 to 5 years after presentation (HR 3.06, 95% CI 1.71 to 5.50).

White Matter Lesions and Silent or Covert Cerebral Infarcts

The mechanisms mediating cognitive disorder in cardiovascular diseases, including hypertension and atherosclerosis, are not entirely clear but appear to be related to central nervous system changes, including overt stroke events and covert cerebral infarcts. These covert cerebral infarcts are non-clinical events that are detected by magnetic resonance imaging of the brain, such as silent cerebral infarcts and white matter lesions. White matter lesions originate from demyelination, gliosis, cerebral infarct, and small vessel disease. White matter lesions on magnetic resonance imaging have been associated with cognitive decline, especially speed of cognitive processes. A meta-analysis showed that white matter lesions were associated with stroke (HR 3.3, 95% CI 2.6 to 4.4), dementia (HR 1.9, 95% CI 1.3 to 2.8), and death (HR 2.0, 95% CI 1.6 to 2.7). Furthermore, cardiovascular risk conditions of hypertension (odds ratio 1.73, 95% CI 1.23 to 2.42) and diabetes mellitus (odds ratio 3.68, 95% CI 1.89 to 7.19) have also been associated with covert or silent cerebral infarcts. Silent or covert cerebral infarcts appear meaningful, being associated with cognitive decline, increased risk of stroke, and dementia.

Atrial Fibrillation and Risk of Embolic Events

The extent to which AF is related to cognitive impairment is unclear. Although AF is associated with many cardiovascular conditions, it is also an established risk factor for ischemic stroke and systemic thromboembolism. AF is associated with an 3- to 5-fold increase in the risk of stroke. Stroke risk in AF patients increased with age, and up to 30% of strokes were in people aged >80 years. Among patients with coronary heart disease or heart failure, AF was associated with a 2-fold increase in stroke risk for men and a 3-fold increase for women. Strokes secondary to AF had worse prognoses than strokes in patients without AF.

Overview of Anticoagulation for Atrial Fibrillation

Risk stratification and stroke prevention are critical to the management of AF patients, and the current European and US guidelines for the management of AF are similar in their recommendations. Oral anticoagulation is important in patients at high risk for stroke because it decreases the stroke rate by nearly 80%, and patients at the highest risk for stroke derive the most benefit. One of the most commonly used anticoagulants is adjusted-dose warfarin, which reduces stroke risk by 64% relative to aspirin. Relative to aspirin, warfarin approximately doubles the risk of intracranial and major extracranial hemorrhage, but the absolute rate of intracranial hemorrhage with warfarin is low at 0.2% to 0.4% per year.

A number of targeted non-vitamin K antagonist oral anticoagulants are now approved by the US Food and Drug Administration for stroke prevention in nonvalvular AF, including dabigatran (direct thrombin inhibitor), rivaroxaban (factor Xa inhibitor), apixaban (factor Xa inhibitor), and
Cognitive Function in Atrial Fibrillation  Cao et al

Table 1. Comparative Effectiveness Trials of Non–Vitamin K Oral Anticoagulants Versus Warfarin

<table>
<thead>
<tr>
<th></th>
<th>Apixaban (ARISTOTLE)</th>
<th>Dabigatran Low-Dose (RE-LY)</th>
<th>Dabigatran High-Dose (RE-LY)</th>
<th>Rivaroxaban (ROCKET)</th>
<th>Edoxaban Low-Dose (ENGAGE)</th>
<th>Edoxaban High-Dose (ENGAGE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>18 201</td>
<td>18 113</td>
<td>14 264</td>
<td>21 105</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean CHADS2 score</td>
<td>2.1±1.1</td>
<td>2.1±1.1</td>
<td>2.2±1.2</td>
<td>3.5±0.9</td>
<td>2.8±1.0</td>
<td>2.8±1.0</td>
</tr>
<tr>
<td>Medication dose</td>
<td>5 mg BID</td>
<td>110 mg BID</td>
<td>150 mg BID</td>
<td>20 mg daily</td>
<td>30 mg daily</td>
<td>60 mg daily</td>
</tr>
<tr>
<td>Stroke or systemic embolism, HR (95% CI)</td>
<td>0.79 (0.66 to 0.95)</td>
<td>0.91 (0.74 to 1.11)</td>
<td>0.66 (0.53 to 0.82)</td>
<td>0.79 (0.66 to 0.96)</td>
<td>1.07 (0.87 to 1.31)</td>
<td>0.79 (0.63 to 0.99)</td>
</tr>
<tr>
<td>Ischemic stroke, HR (95% CI)</td>
<td>0.92 (0.74 to 1.13)</td>
<td>1.11 (0.89 to 1.40)</td>
<td>0.76 (0.60 to 0.98)</td>
<td>0.91 (0.73 to 1.13)</td>
<td>1.41 (1.19 to 1.67)</td>
<td>1.00 (0.83 to 1.19)</td>
</tr>
<tr>
<td>Total mortality, HR (95% CI)</td>
<td>0.89 (0.80 to 0.988)</td>
<td>0.91 (0.80 to 1.03)</td>
<td>0.88 (0.77 to 1.00)</td>
<td>0.85 (0.70 to 1.02)</td>
<td>0.87 (0.79 to 0.96)</td>
<td>0.92 (0.83 to 1.01)</td>
</tr>
<tr>
<td>Intracranial hemorrhage, HR (95% CI)</td>
<td>0.42 (0.30 to 0.58)</td>
<td>0.31 (0.20 to 0.47)</td>
<td>0.40 (0.27 to 0.60)</td>
<td>0.67 (0.47 to 0.93)</td>
<td>0.30 (0.21 to 0.43)</td>
<td>0.47 (0.34 to 0.63)</td>
</tr>
<tr>
<td>Major bleeding, HR (95% CI)</td>
<td>0.69 (0.60 to 0.80)</td>
<td>0.80 (0.69 to 0.93)</td>
<td>0.93 (0.81 to 1.07)</td>
<td>1.04 (0.95 to 1.13)</td>
<td>0.47 (0.41 to 0.55)</td>
<td>0.80 (0.71 to 0.91)</td>
</tr>
</tbody>
</table>

HR indicates hazard ratio.

edoxaban (factor Xa inhibitor) (Table 1).55–58 The most important benefits that these newer drugs offer over warfarin are a >50% reduction in intracranial bleeding and a 10% reduction in all-cause mortality.54 In fact, the novel oral anticoagulants appear to have similar risk profiles to low-dose aspirin in terms of major bleeding and intracranial hemorrhage.59

Beyond Stroke: Atrial Fibrillation and Cognitive Decline

The role of AF in cognitive decline, independent of stroke, is uncertain. Many studies have found that AF is associated with cognitive decline,40,44,60,61 but it is less clear whether this association is directly related to AF itself or is a function of the population in which AF occurs, that is, an aging cohort with multiple comorbidities (Table 2).22,41,43,44,62–83 Cognitive impairment has been identified in as many as 69% of AF patients.84 In 1 study, AF was associated with increased risk of cognitive decline, new dementia, loss of independence in everyday life, and admission to long-term care facilities.22 Conversely, others have found no differences in cognitive decline between AF and non-AF patients.44

Multiple potential mechanisms explain the association between AF and cognitive decline. Cerebral microbleeds increase with age and anticoagulation,85 and microbleeds are associated with cognitive decline.86 Cerebral hypoperfusion during AF may contribute to cognitive impairment. Decreased diastolic cerebral perfusion has also been associated with AF,87 and irregularity of ventricular contraction during AF affects preload and cardiac output, which may result in a decreased mean cerebral flow.88 Inflammatory markers, including C-reactive protein, TNF-α, and IL-6, are associated with AF.89–91 Inflammatory markers such as C-reactive protein and IL-6 have been associated with cognitive decline and Alzheimer’s disease.92,93 Given the propensity to form thrombus (micro- and macrothrombi) in the left atrium and atrial appendage in the setting of AF, it is biologically plausible that AF could contribute to cognitive impairment through chronic ischemic–embolic insults, even without overt evidence of clinical stroke. Cognitive dysfunction in AF patients has been correlated with less effective anticoagulation, more vascular events, and more bleeding, likely related to decreased adherence to prescribed oral anticoagulation.45 In support of the hypothesis of chronic subclinical embolic contribution to cognitive decline in AF, silent infarcts are significantly more frequent among patients with AF than in those without AF (Table 3).39,41,43,73,94–97 The prevalence of silent cerebral infarcts among patients with AF varies widely in the literature but has been reported to be as high as 92%, which is twice the prevalence of silent cerebral infarcts among patients with normal sinus rhythm.39,73 Of the 92% of patients with silent cerebral infarcts, 61% had CHA2DS2-VASc scores ≤1, meaning they were not currently recommended to be treated with oral anticoagulation based on the AF guidelines in the United States.73 Furthermore, cognitive impairment rates are higher among AF patients than non-AF patients, even after excluding all patients with abnormalities on magnetic resonance imaging of the brain.50 Among AF patients with neurological imaging, the number of abnormal brain areas with tissue loss was significantly
Table 2. Data on Cognitive Decline in Atrial Fibrillation

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Patients</th>
<th>AF Patients</th>
<th>Population</th>
<th>Follow-up</th>
<th>Cognitive Function Assessment</th>
<th>AF Association Cognitive Decline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Farina</td>
<td>1997</td>
<td>74</td>
<td>37</td>
<td>21 PAF, 16 persistent AF</td>
<td>Cross-section</td>
<td>MMSE*</td>
<td>Statistically significant for persistent, not significant for paroxysmal</td>
</tr>
<tr>
<td>Ott</td>
<td>1997</td>
<td>6584</td>
<td>195</td>
<td>Mean age 69±9 years</td>
<td>Cross-section</td>
<td>MMSE and Geriatric Mental State Schedule</td>
<td>Adjusted OR 1.7 (1.2 to 2.5)</td>
</tr>
<tr>
<td>Kilander</td>
<td>1998</td>
<td>952</td>
<td>44</td>
<td>Mean age 72±1 years</td>
<td>Cross-section</td>
<td>Trail Making Tests A and B, MMSE</td>
<td>Unadjusted, statistically significant</td>
</tr>
<tr>
<td>O’Connell</td>
<td>1998</td>
<td>81</td>
<td>27</td>
<td>Mean age 72±1 years</td>
<td>Cross-section</td>
<td>Mini-Mental Status†</td>
<td>MMSE not statistically significant</td>
</tr>
<tr>
<td>Rozzini</td>
<td>1999</td>
<td>269</td>
<td>55</td>
<td>13 PAF, 42 persistent AF</td>
<td>Cross-section</td>
<td>MMSE</td>
<td>Adjusted OR for paroxysmal AF 1.2 (0.3 to 4.8), OR for persistent AF 3.2 (1.5 to 6.6)</td>
</tr>
<tr>
<td>Elias</td>
<td>2006</td>
<td>1011</td>
<td>59</td>
<td>Men, mean age 61 years</td>
<td>Cross-section</td>
<td>Wechsler Adult Intelligence Scale‡</td>
<td>Adjusted, statistically significant</td>
</tr>
<tr>
<td>Jozwiak</td>
<td>2006</td>
<td>2314</td>
<td>547</td>
<td>Median age 80 years (75 to 86)</td>
<td>Cross-section</td>
<td>MMSE</td>
<td>OR 1.56 (1.27 to 1.92, P=0.0001)</td>
</tr>
<tr>
<td>Debette</td>
<td>2007</td>
<td>83</td>
<td>32</td>
<td>Mean age 62 years</td>
<td>Cross-section</td>
<td>MMSE</td>
<td>Adjusted OR 8.1 (1.9 to 34.6, P=0.008)</td>
</tr>
<tr>
<td>Rastas</td>
<td>2007</td>
<td>553</td>
<td>122</td>
<td>85 years and older</td>
<td>Cross-section</td>
<td>MMSE§</td>
<td>Unadjusted, not statistically significant</td>
</tr>
<tr>
<td>Knecht</td>
<td>2008</td>
<td>533</td>
<td>87</td>
<td>Mean age 63±8 years</td>
<td>Cross-section</td>
<td>Composite†</td>
<td>Adjusted, statistically significant</td>
</tr>
<tr>
<td>Bilato</td>
<td>2009</td>
<td>1576</td>
<td>135</td>
<td>Mean age 74 years</td>
<td>Cross-section</td>
<td>MMSE</td>
<td>Adjusted OR 1.14 (0.73 to 1.80)</td>
</tr>
<tr>
<td>Bellomo</td>
<td>2012</td>
<td>57</td>
<td>26</td>
<td>Mean age 72±8 years</td>
<td>Cross-section</td>
<td>MMSE</td>
<td>Adjusted, statistically significant</td>
</tr>
<tr>
<td>Gaita</td>
<td>2013</td>
<td>270</td>
<td>180</td>
<td>61% with CHA2-Ds2-VaSc &lt;2</td>
<td>Cross-section</td>
<td>Repeatable Battery for the Assessment of Neuropsychological Status</td>
<td>Unadjusted, statistically significant</td>
</tr>
<tr>
<td>Stefansdóttir</td>
<td>2013</td>
<td>4251</td>
<td>330</td>
<td>Mean age 76±5 years</td>
<td>Cross-section</td>
<td>Modified California Verbal Learning Test</td>
<td>Adjusted, statistically significant</td>
</tr>
<tr>
<td>Horstmann</td>
<td>2014</td>
<td>788</td>
<td>165</td>
<td>Mean age 67±14 years</td>
<td>Cross-section</td>
<td>Informant questionnaire on cognitive decline in the elderly</td>
<td>OR of 2.97 (1.0 to 8.8, P=0.05)</td>
</tr>
<tr>
<td>Tilvis</td>
<td>2004</td>
<td>650</td>
<td></td>
<td>Mean 5 years</td>
<td>MMSE and Clinical Dementia Rating</td>
<td>RR 2.8</td>
<td></td>
</tr>
<tr>
<td>Forti</td>
<td>2006</td>
<td>431</td>
<td>13</td>
<td>Mean age 75±5 years</td>
<td>Mean of 4 years</td>
<td>MMSE</td>
<td>Adjusted HR 1.10 (0.40 to 3.03)</td>
</tr>
<tr>
<td>Park</td>
<td>2007</td>
<td>362</td>
<td>174</td>
<td>Mean age 76 years</td>
<td>Mean 3 years</td>
<td>MMSE</td>
<td>No significant association</td>
</tr>
<tr>
<td>Peters</td>
<td>2009</td>
<td>3336</td>
<td>190</td>
<td>Mean age 53±6 years</td>
<td>Mean of 2 years</td>
<td>MMSE</td>
<td>HR 1.031 (0.619 to 1.718)</td>
</tr>
<tr>
<td>Bunch</td>
<td>2010</td>
<td>37 025</td>
<td>10 161</td>
<td>Mean age 61±18 years</td>
<td>Mean of 5 years</td>
<td>ICD-9 code for dementia</td>
<td>Adjusted OR 1.73 (P=0.001)</td>
</tr>
<tr>
<td>Dublin</td>
<td>2011</td>
<td>3045</td>
<td>402</td>
<td>Median age 74 years</td>
<td>Mean of 7 years</td>
<td>Cognitive Abilities Screening Instrument</td>
<td>Adjusted HR 1.50 (1.16 to 1.94)</td>
</tr>
</tbody>
</table>

Continued
The areas with tissue loss were usually located in the cortex, but there was no difference in the size of the lesions between control and AF patients. Silent cerebral infarction was not a predictor of stroke in AF patients. AF has also been associated with smaller brain volumes than in patients without AF, and AF has been associated with lower total brain mass, gray matter, and white matter. The longer AF was present, the more brain volume decreased, and this was noted even without overt cerebral infarction. The memory domain appeared dispropor-

Table 2. Continued

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Patients</th>
<th>AF Patients</th>
<th>Population</th>
<th>Follow-up</th>
<th>Cognitive Function Assessment</th>
<th>AF Association Cognitive Decline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li80</td>
<td>2011</td>
<td>650</td>
<td>30</td>
<td>Mean age 67 years</td>
<td>Mean of 5 years</td>
<td>MMSE</td>
<td>Adjusted OR 1.09 (0.54 to 2.20, P=0.82)</td>
</tr>
<tr>
<td>Marengoni81</td>
<td>2011</td>
<td>785</td>
<td>68</td>
<td>Mean age 78 years</td>
<td>Mean of 4 years</td>
<td>MMSE</td>
<td>Adjusted HR 0.8 (0.4 to 1.5)</td>
</tr>
<tr>
<td>Marzona22</td>
<td>2012</td>
<td>31 546</td>
<td>3068</td>
<td>Mean age 67±7 years</td>
<td>Median 56 months</td>
<td>MMSE</td>
<td>HR 1.30 (1.14 to 1.49)</td>
</tr>
<tr>
<td>Haring82</td>
<td>2013</td>
<td>6455</td>
<td>255</td>
<td>Women age 60 to 84 years</td>
<td>Mean of 8 years</td>
<td>Annual modified MMSE</td>
<td>HR 1.25 (0.78 to 2.0)</td>
</tr>
<tr>
<td>Thacker83</td>
<td>2013</td>
<td>5150</td>
<td>552</td>
<td>Mean age 73±5 years</td>
<td>Mean of 7 years</td>
<td>Annual modified MMSE</td>
<td>Adjusted, statistically significant</td>
</tr>
<tr>
<td>Chen43</td>
<td>2014</td>
<td>935</td>
<td>48</td>
<td>Mean age 62±4 years</td>
<td>Median 10.6 years</td>
<td>Delayed word recall, digit symbol substitution, first-letter word fluency</td>
<td>Statistically significant</td>
</tr>
</tbody>
</table>

AF indicates atrial fibrillation; HR, hazard ratio; ICD-9, International Classification of Diseases, 9th Revision; MMSE, Mini Mental Status Exam; OR, odds ratio; PAF, paroxysmal atrial fibrillation; RR, relative risk. Data are displayed as median (interquartile range), mean +/- standard deviation, OR (95% confidence interval), and HR (95% confidence interval).

*Also includes Weschler Adult Intelligence, Logical Memory Test, Paired Associated Learning Test, Corsi’s Block Tapping Test, Attentional Matrices, Raven Progressive Matrices, Judgment of Line Orientation, Rey-Osterrieth Complex, Verbal Fluency for Letters, Wisconsin Sorting Card Test.

*Also includes National Adult Reading Test, Wechsler Logical Memory Test, Rey Complex Figure Test, Digit Span, Paced Auditory Serial Addition Test.

*Also includes Wechsler Memory Scale, Hooper Visual Organization Test, Halstead-Reitan Battery.

*Also includes Short Portable Mental Status Questionnaire, Clinical Dementia Rating.

*Auditory verbal learning test, Stroop test, Trail-making test, Wechsler Memory Scale, category and letter fluency, Rey-Osterrieth complex figure test, digit symbol substitution test.

greater compared with non-AF patients. The areas with tissue loss were usually located in the cortex, but there was no difference in the size of the lesions between control and AF patients. Silent cerebral infarction was not a predictor of stroke in AF patients. AF has also been associated with smaller brain volumes than in patients without AF, and AF has been associated with lower total brain mass, gray matter, and white matter. The longer AF was present, the more brain volume decreased, and this was noted even without overt cerebral infarction. The memory domain appeared dispropor-

Table 3. Data on Silent Cerebral Infarct in Atrial Fibrillation

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Patients</th>
<th>Population</th>
<th>Design</th>
<th>Silent Cerebral Infarcts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petersen96</td>
<td>1987</td>
<td>58</td>
<td>29 (50%) with AF</td>
<td>AF patients matched to non-AF patients, single CT head</td>
<td>48% of AF patients and 28% of non-AF patients (P=0.10)</td>
</tr>
<tr>
<td>Kempster97</td>
<td>1988</td>
<td>222</td>
<td>54 (24%) with AF</td>
<td>Retrospective analysis of patients with CT head</td>
<td>13% of AF patients and 4% of non-AF patients (P=0.05)</td>
</tr>
<tr>
<td>Raiha95</td>
<td>1993</td>
<td>204</td>
<td>30 (15%) with AF</td>
<td>CT head scans from a geriatrics clinic</td>
<td>73% of AF patients and 48% of non-AF patients (P=0.0095)</td>
</tr>
<tr>
<td>Ezekowitz39</td>
<td>1995</td>
<td>516</td>
<td>516 (100%) with AF</td>
<td>Noncontrast CT head done at beginning and end of study</td>
<td>15% of AF patients</td>
</tr>
<tr>
<td>de Leeuw94</td>
<td>2000</td>
<td>1077</td>
<td>28 (3%) with AF</td>
<td>RR of white matter lesions 2.2 (95% CI 1.0, 5.2)</td>
<td></td>
</tr>
<tr>
<td>Gaita73</td>
<td>2013</td>
<td>270</td>
<td>180 (67%) with AF</td>
<td>90 sinus rhythm, 90 paroxysmal AF, and 90 persistent AF</td>
<td>89% of paroxysmal AF, 92% of persistent AF, and 46% sinus rhythm</td>
</tr>
<tr>
<td>Stefansdottir41</td>
<td>2013</td>
<td>4251</td>
<td>330 (8%) with AF</td>
<td>Single MRI brain</td>
<td>49% of AF patients and 29% of non-AF patients (P=0.001)</td>
</tr>
<tr>
<td>Chen43</td>
<td>2014</td>
<td>935</td>
<td>48 (5%) with AF</td>
<td>Serial MRI scan at baseline and 9 to 13 years later</td>
<td>33% of AF patients and 17% of non-AF patients</td>
</tr>
</tbody>
</table>

AF indicates atrial fibrillation; CT, computed tomography; MRI, magnetic resonance imaging; RR, relative risk.
Evaluating Cognitive Decline in Atrial Fibrillation

There is no single, universally accepted test to assess cognitive function. The Alzheimer’s Association provided 16 cognitive function tools that were evaluated in several review articles and that could be used by primary care providers to assess cognitive impairment (Table 4). One of the most commonly reported cognitive function tests in the research literature is the Mini Mental Status Examination (MMSE), which has been in use since 1975 to detect memory loss and to assess cognitive function. Typically, scores <24 are suggestive of dementia, and scores of 24 or 25 are associated with increased risk for developing dementia within 3 years. Poor performance on the MMSE in the first week after acute ischemic stroke is one of the important predictors of cognitive decline over the ensuing 3 months. Many of the existing studies evaluating cognitive impairment in AF have used the MMSE to evaluate cognitive decline. Among AF patients, low scores on the MMSE have been associated with out-of-range International Normalized Ratios and an increased risk of vascular events and bleeding in AF patients.

There were concerns that the MMSE was less sensitive with mild cognitive impairment. The Montreal Cognitive Assessment (MoCA) was developed as a screening tool for early cognitive decline, and the MoCA was found to have a sensitivity of 90% in identifying mild cognitive impairment compared with a sensitivity of only 18% with the MMSE. The MoCA was also more sensitive in detecting mild cognitive impairment than the Cognitive Capacity Screening Examination (sensitivity 74%) and the DemTect (sensitivity 80%), which were 2 other cognitive function screening tests.

Vascular cognitive impairment, as seen in AF patients with stroke and transient ischemic attack, was associated with deficits in executive function, attention, and speed of information processing more than other domains. The MMSE places more emphasis on language and memory than on other cognitive domains. The MoCA weighs executive function and attention more heavily than the MMSE, and the MoCA has been shown to be superior to the MMSE in identifying cognitive impairment in patients with vascular disease due to TIA or stroke.

Antithrombotics and Cognitive Decline in Atrial Fibrillation

There is variation across the available data regarding the effects of antithrombotic therapy on cognitive function among patients with AF. In a nonrandomized study, warfarin therapy did not affect the association between brain volume loss and AF. In another study, the use of antithrombotic agents did not affect cognitive decline among AF patients. Similarly, Park and colleagues found no differences in cognitive decline among AF patients on aspirin, warfarin, or neither. An observational study, however, found a trend toward an association between warfarin use and lower rates of cognitive decline among patients with AF. The Birmingham Atrial Fibrillation Treatment of the Aged Study randomized 973 patients with CHADS2-VASc of at least 2 to warfarin versus aspirin and found a non–statistically significant trend toward decreased cognitive decline at 33 months within the warfarin group. The clinical benefit of warfarin was seen only when a high frequency of time is in the therapeutic range. Data from the Atrial Fibillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W) found that among patients who had AF, who had a mean CHADS2 score of 2, and who were on warfarin, cognitive dysfunction was associated with lower time in the therapeutic range of anticoagulation, suggesting that maintaining therapeutic anticoagulation may decrease cognitive decline. Because non–vitamin K oral anticoagulants mitigate the challenges of time in the therapeutic range, there has been speculation that they may be able to slow or reverse cognitive decline among AF patients.

Additional prospective work is needed to quantify cognitive function and rates of cognitive decline among AF patients.

Table 4. Cognitive Function Tests That Could be Used to Screen for Cognitive Impairment

<table>
<thead>
<tr>
<th>Test Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>7-Minute Screener</td>
</tr>
<tr>
<td>Abbreviated Mental Test</td>
</tr>
<tr>
<td>Cambridge Cognitive Examination</td>
</tr>
<tr>
<td>Clock Drawing Test</td>
</tr>
<tr>
<td>General Practitioner Assessment of Cognition</td>
</tr>
<tr>
<td>Mini-Cog</td>
</tr>
<tr>
<td>Memory Impairment Screen</td>
</tr>
<tr>
<td>Mini Mental State Examination</td>
</tr>
<tr>
<td>Montreal Cognitive Assessment</td>
</tr>
<tr>
<td>Rowland University Dementia Assessment</td>
</tr>
<tr>
<td>Short and Sweet Screening Instrument</td>
</tr>
<tr>
<td>Short Blessed Test</td>
</tr>
<tr>
<td>St. Louis University Mental Status</td>
</tr>
<tr>
<td>Short Portable Mental Status Questionnaire</td>
</tr>
<tr>
<td>Short Test of Mental Status</td>
</tr>
<tr>
<td>Time and Change Test</td>
</tr>
</tbody>
</table>
compared with non-AF patients, especially by using more sensitive tools such as the MoCA. An ongoing clinical trial is the Aspirin in Reducing Events in the Elderly (ASPREE) study (ClinicalTrials.gov identifier NCT01038583), which is comparing aspirin and placebo for prevention of death, dementia, or disability in 19,000 patients. A neuroimaging substudy (ENVIS-ion) will evaluate the effect of aspirin on the development of white matter hyperintense lesions, and results are expected in 2018.112 More data are also needed on the relationship between cognitive decline with AF and estimated vascular embolic risk, as well as how this may be affected by anticoagulation. These findings may be particularly important among subpopulations of AF patients for whom the US guidelines do not currently recommended anticoagulation therapy over aspirin or any antithrombotic therapy (CHA2DS2-VASc score of 0 or 1).

Conclusions
Most studies suggest that AF is independently associated with cognitive decline, even among patients with no clinical history of stroke. Cognitive decline is associated with stroke and silent cerebral infarcts, and patients with AF have higher rates of silent cerebral infarcts than patients without AF. The impact of anticoagulation on silent cerebral infarcts remains unknown. Cognitive decline is an important public health concern, and clinical trials are needed to evaluate the effect of oral anticoagulation on cognitive decline in patients with AF.

Disclosures
Ms Cao has no disclosures to report. Dr Pokorney reports modest research grant support from Astra Zeneca, Gilead, and Boston Scientific; modest Advisory Board from Janssen Pharmaceuticals. Drs Welsh-Bohmer and Hayden have received research support from Takeda and Zinfandel Pharmaceutical Companies. Dr Newby has received research grant funding for EARLY ACS through Duke/Duke Clinical Research Institute from Merck-Scherling Plough, Amgen, Inc, Amylin, AstraZeneca, Eli Lilly, Daichi-Sankyo, diaDexus, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, Murdock Study, Regado Biosciences, NHLBI, Novartis, and Roche.

References
Cognitive Function in Atrial Fibrillation  Cao et al


Cognitive Function in Atrial Fibrillation  

Cao et al

fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J. 2008;29:2125–2132.


**Key Words:** anticoagulation • atrial fibrillation • cognitive impairment • silent brain infarction • stroke
Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?  
Lin Cao, Sean D. Pokorney, Kathleen Hayden, Kathleen Welsh-Bohmer and L. Kristin Newby

*J Am Heart Assoc.* 2015;4:e001573; originally published August 3, 2015;  
doi: 10.1161/JAHA.114.001573

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue,  
Dallas, TX 75231  
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://jaha.ahajournals.org/content/4/8/e001573